natgillin/translations-raw huggingface dataset:
In very rare cases, severe reactions at the urethral meatus have resulted in dysuria in women (see section 4.4).
U vrlo rijetkim slučajevima ozbiljne reakcije u području uretralnog ušća dovele do otežanog mokrenja kod žena.
In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.
U vrlo rijetkim slučajevima u nekih su se bolesnika s teškim oštećenjem prednjeg prozirnog sloja oka (rožnice) pojavile mutne mrlje na rožnici zbog nakupljanja kalcija tijekom liječenja.
In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.
U vrlo rijetkim slučajevima u nekih su se bolesnika s teškim oštećenjem rožnice pojavile mutne mrlje na rožnici zbog nakupljanja kalcija tijekom liječenja.
In very rare cases, temporary local reactions occur at the injection site in the form of a normally painless nodule of 0.5 to 1 cm in sheep and of 0.5 to 3 cm in cattle which disappears within 14 days, at the latest.
U vrlo rijetkim slučajevima na mjestu injiciranja javljaju se privremene lokalne reakcije, većinom u obliku bezbolnog čvorića promjera od 0,5 do 1 cm u ovaca, odnosno od 0,5 do 3 cm u goveda, koji nestaje najkasnije u roku od 14 dana.
In very rare cases, temporary local reactions occur at the injection site in the form of a normally painless nodule of 0.5 to 1 cm in sheep and of 0.5 to 3 cm in cattle which disappears within 14 days, at the latest.
U vrlo rijetkim slučajevima, se na mjestu injiciranja javljaju se privremene lokalne reakcije većinom u obliku bezbolnog čvorića promjera od 0,5 do 1 cm u ovaca, odnosno od 0,5 do 3 cm u goveda, koji nestaje najkasnije u roku od 14 dana.
In very rare cases, the use of the veterinary medicinal product has been associated with hearing impairment, usually temporary, and primarily in geriatric dogs.
U vrlo malo slučajeva (< 0.01%) prilikom primjene ovog VMP primijećena je pojava oštećenja sluha, uglavnom privremeno i najčešće kod starih pasa.
In very rare cases, these have progressed to suicidal thoughts and self-endangering behaviour - sometimes after only a single dose of levofloxacin (see section 4.8).
U vrlo rijetkim slučajevima ove su reakcije progredirale do suicidalnih misli i samougrožavajućeg ponašanja - ponekad nakon samo jedne doze levofloksacina (vidjeti dio 4.8).
In very rare cases, they may be serious or fatal.
U vrlo rijetkim slučajevima nuspojave mogu biti ozbiljne ili smrtonosne.
In very rare cases, transient lethargy in piglets has been observed.
U vrlo rijetkim slučajevima, uočena je prolazna letargija prasadi.
In very rare cases, Type-I Hypersensitivity reactions (facial swelling, allergic pruritus) have been observed.
Također, u vrlo malo slučajeva (< 0.01%) primijećena je i reakcija preosjetljivosti tipa I ( znojenje lica, alergijski pruritis ).
In very rare occasions, abcessation may be observed.
Vrlo rijetko mogu se zamijetiti apscesi.
In very severe cases this could lead to kidney failure.
U vrlo teškim slučajevima ono može prouzročiti zatajenje bubrega.
In very small children, the injection may be given into the thigh muscle.
U vrlo male djece injekcija se može dati u bedreni mišić.
In view of its action on cellular deoxyribonucleic acid (DNA) 6–mercaptopurine is potentially carcinogenic and consideration should be given to the theoretical risk of carcinogenesis with this treatment.
S obzirom na njegov učinak na staničnu deoksiribonukleinsku kiselinu (DNK) 6-merkaptopurin je potencijalno kancerogen pa je tijekom liječenja potrebno uzeti u obzir teorijski rizik od kancerogeneze.
In view of limited safety and efficacy data in patients with secondary AML, filgrastim should be administered with caution.
Budući da su podaci o sigurnosti primjene i djelotvornost u bolesnika sa sekundarnom akutnim mijeloičnom leukemijom (AML) ograničeni, filgrastim tim bolesnicima treba davati oprezno.
In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer.
S obzirom na gore navedeno, u nekim kliničkim situacijama transfuzija krvi bi trebala biti tretman izbora u liječenju anemije kod bolesnika s malignim bolestima.
In view of the above, it is considered that cutaneous amyloidosis at the injection site should be reflected as an adverse reaction in the product information of Fuzeon.
Uzimajući u obzir navedeno, smatra se da je kožnu amiloidozu na mjestu injiciranja potrebno uvrstiti kao nuspojavu u informacije o lijeku Fuzeona.
In view of the indication, administration of stiripentol during pregnancy and in women of childbearing potential would not be expected.
Ne očekuje se postojanje indikacije za primjenu stiripentola tijekom trudnoće i u žena koje mogu rađati.
In view of the lack of genotoxicity of stiripentol and the well known, special susceptibility of the mouse liver to tumour formation in the presence of hepatic enzyme induction, this finding is not considered to indicate a risk of tumorigenicity in patients.
Glede nedostatka genotoksičnosti stiripentola, a dobro poznate, osobite podložnosti mišje jetere ka stvaranju tumora u prisustvu indukcije hepatičkih enzima, ne smatra se da ovaj nalaz ukazuje na rizik od tumora u ljudi
In view of the lack of genotoxicity of stiripentol and the well known, special susceptibility of the mouse liver to tumour formation in the presence of hepatic enzyme induction, this finding is not considered to indicate a risk of tumorigenicity in patients.
Glede nedostatka genotoksičnosti stiripentola, a dobro poznate, osobite podložnosti mišje jetere ka stvaranju tumora u prisustvu indukcije hepatičkih enzima, ne smatra se da ovaj nalaz ukazuje na rizik od tumora u ljudi.
In view of the long half-life of amiodarone the potential for drug interaction may exist for weeks after discontinuation of amiodarone (see sections 4.2 and 4.4).
S obzirom na dugačak poluvijek amiodarona, potencijal za interakciju lijeka može postojati tjednima nakon prekida primjene amiodarona (vidjeti dijelove 4.2 i 4.4).
In view of the MAO inhibitory activity of safinamide, concomitant administration of Xadago and sympathomimetics, such as those present in nasal and oral decongestants or cold medicinal products containing ephedrine or pseudoephedrine, requires caution (see section 4.4).
S obzirom na MAO inhibicijsku aktivnost safinamida, istovremena primjena lijeka Xadago i simpatomimetika, kao što su oni prisutni u nazalnim i oralnim dekongestivima ili lijekovima za prehladu koji sadrže efedrin ili pseudoefedrin, zahtijeva oprez (vidjeti dio 4.4).
In view of the MAO inhibitory activity of safinamide, the concomitant administration of Xadago and dextromethorphan is not recommended, or if concomitant treatment is necessary, it should be used with caution (see section 4.4).
S obzirom na MAO inhibicijsku aktivnost safinamida, istovremena primjena lijeka Xadago i dekstrometorfana se ne preporučuje, ili ako je istovremeno liječenje neophodno, potrebno ga je oprezno primijeniti (vidjeti dio 4.4).
In view of the possible risk of microbial contamination, Biograstim syringes are for single use only.
Zbog moguće mikrobiološke kontaminacije, štrcaljke s lijekom Biograstim namijenjene su samo za jednokratnu primjenu.
In view of the possible risk of microbial contamination, Filgrastim HEXAL syringes are for single use only.
S obzirom na mogući rizik mikrobiološke kontaminacije, Filgrastim HEXAL štrcaljke su namijenjene samo za jednokratnu primjenu.
In view of the possible risk of microbial contamination, Lonquex syringes are for single use only.
Zbog mogućeg rizika od mikrobiološke kontaminacije, štrcaljke Lonquexa namijenjene su samo za jednokratnu uporabu.
In view of the possible risk of microbial contamination, Nivestim syringes are for single use only.
Imajući u vidu mogući rizik od mikrobiološke kontaminacije, štrcaljke Nivestima namijenjene su isključivo za jednokratnu uporabu.
In view of the possible risk of microbial contamination, Ratiograstim syringes are for single use only.
Zbog moguće mikrobiološke kontaminacije, štrcaljke s lijekom Ratiograstim namijenjene su samo za jednokratnu primjenu.
In view of the possible risk of microbial contamination, Tevagrastim syringes are for single use only.
Zbog moguće mikrobiološke kontaminacije, štrcaljke s lijekom Tevagrastim namijenjene su samo za jednokratnu primjenu.
In view of the potential impact of bisphosphonates, including zoledronic acid, on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 μmol/l or ≥ 4.5 mg/dl for patients with TIH and ≥ 265 μmol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of Zoledronic Acid Teva is not recommended in patients with severe renal impairment.
S obzirom na mogući utjecaj bisfosfonata, uključujući i zoledronatnu kiselinu, na funkciju bubrega, nedostatak kliničkih podataka o sigurnosti primjene u bolesnika s teškim oštećenjem funkcije bubrega (u kliničkim ispitivanjima definiranim kao kreatinin u serumu ≥ 400 μmol/l ili ≥ 4,5 mg/dl u bolesnika s hiperkalcemijom izazvanom tumorom, odnosno ≥ 265 μmol/l ili ≥ 3,0 mg/dl u bolesnika s rakom i metastazama u kostima) na početku liječenja i ograničene farmakokinetičke podatke u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) na početku liječenja, ne preporučuje se primjena Zoledronatne kiseline Teva u bolesnika s teškim oštećenjem funkcije bubrega.
In virologically suppressed HIV-1 infected patients
U virološki suprimiranih pacijenata zaraženih virusom HIV-1
In virologically suppressed patients, the clinical relevance of this reduction can be expected to be limited (see section 5.1).
U pacijenata s virološkom supresijom može se očekivati ograničen klinički značaj ovog smanjenja (vidjeti dio 5.1).
In virologically-suppressed patients
U pacijenata kod kojih je virus suprimiran
In vitro (14C)-lenalidomide binding to plasma proteins was low with mean plasma protein binding at 23% and 29% in multiple myeloma patients and healthy volunteers, respectively.
In vitro vezanje (14C)-lenalidomida na proteine plazme bilo je nisko sa srednjim vezivanjem na proteine plazme od 23% u bolesnika s multiplim mijelomom te 29% u zdravih dobrovoljaca.
In vitro (14C)-lenalidomide binding to plasma proteins was low with mean plasma protein binding at 23% and 29% in multiple myeloma patients and healthy volunteers, respectively.
In vitro vezanje (14C)-lenalidomida na proteine plazme bilo je nisko, sa srednjim vezivanjem na proteine plazme od 23% u bolesnika s multiplim mijelomom te 29% u zdravih dobrovoljaca.
In vitro / in vivo studies indicate that CYP3A4, CYP3A5, and subsequently uridine diphosphate- glucuronosyltransferases (UGT), are involved in the metabolism of isavuconazole.
Ispitivanja in vitro / in vivo ukazuju da su CYP3A4, CYP3A5 i naknadno uridindifosfat- glukuronoziltransferaze (UGT) uključeni u metabolizam izavukonazola.
In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., and Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 μg/ml.
Zabilježena je aktivnost in vitro protiv kliničkih izolata vrsta iz rodova Acremonium, Alternaria, Bipolaris i Cladophialophora te Histoplasma capsulatum, gdje je najveći broj sojeva bio inhibiran pri koncentracijama vorikonazola u rasponu od 0,05 do 2 µg/ml.
In vitro activity against Dichelobacter nodosus (vir), the bacterial pathogen most commonly associated with infectious pododermatitis (foot rot) in sheep has been demonstrated.
Kod in vitro djelovanja protiv Dichelobacter nodosus (vir), dokazano je, da je bakterijski patogen najčešće povezan sa zaraznim pododermatitisom (zarazna šepavost) u ovaca.
In vitro activity against the following pathogens has been shown, but the clinical significance is unknown: Curvularia spp. and Sporothrix spp.
Dokazana je i aktivnost in vitro protiv patogena iz rodova Curvularia i Sporothrix, no klinički značaj tog nalaza nije poznat.
In vitro and animal data suggest that bromelain can also promote fibrinolysis.
In vitro podaci i podaci prikupljeni u ispitivanjima na životinjama pokazuju da bromelain može potaknuti i fibrinolizu.
In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving tenofovir alafenamide with other medicinal products is low.
In vitro i klinička farmakokinetička ispitivanja interakcija lijekova pokazala su da je mogućnost interakcija posredovanih CYP-sustavom za tenofoviralafenamid s drugim lijekovima mala.
In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP-mediated interactions involving emtricitabine and tenofovir disoproxil fumarate with other medicinal products is low.
In vitro i klinička ispitivanja farmakokinetičkih interakcija pokazala su da je potencijal za interakcije emtricitabina i tenofovirdizoproksilfumarata s drugim lijekovima, posredovane CYP sustavom, nizak.
In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP450 mediated interactions involving emtricitabine and tenofovir disoproxil fumarate with other medicinal products is low.
In vitro i klinička ispitivanja farmakokinetičkih interakcija pokazala su da je potencijal za interakcije posredstvom CYP450, koje uključuju emtricitabin i tenofovirdizoproksilfumarat s drugim lijekovima, nizak.
In vitro and in vivo data in non-target species suggest that the vaccine may provide a degree of cross-protection against L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
In vitro i in vivo podaci ukazuju da cjepivo, u neciljnih vrsta životinja, može pružiti određeni stupanj unakrižne zaštite protiv L. interrogans serogrupa Icterohaemorrhagiae, soj Icterohaemorrhagiae i L. kirschneri serogrupa Grippotyphosa, soj Grippotyphosa.
In vitro and in vivo data in non-target species suggests that the vaccine may provide a degree of cross-protection against L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
In vitro i in vivo podaci ukazuju da cjepivo, u neciljnih vrsta životinja, može pružiti određeni stupanj unakrižne zaštite protiv L. interrogans serogrupa Icterohaemorrhagiae, soj Icterohaemorrhagiae i L. kirschneri serogrupa Grippotyphosa, soj Grippotyphosa.
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-l (COX-I).
Ispitivanja in vitro i in vivo pokazala su da meloksikam inhibira ciklooksigenazu-2 (COX-2) u većoj mjeri nego ciklooksigenazu-1 (COX-1).
In vitro and in vivo studies have shown that oestrogens are partially metabolized by cytochrome P450 enzymes, including CYP3A4.
In vitro i in vivo ispitivanja pokazala su da se estrogeni jednim dijelom metaboliziraju enzimima citokroma P450 uključujući CYP3A4.
In vitro and in vivo studies in humans indicate that amifampridine is metabolised to a single major 3- N-acetylated amifampridine metabolite.
In vitro i in vivo ispitivanja na ljudima ukazuju da se amifampridin metabolizira u jedan glavni metabolit 3-N-acetilirani amifampridin.
In vitro and in vivo studies to date have not detected any activity of the major metabolite (5-carboxy-pirfenidone), even at concentrations or doses greatly above those associated with activity of pirfenidone itself.
Dosadašnja ispitivanja in vitro i in vivo nisu utvrdila nikakvu aktivnost glavnog metabolita (5-karboksi-pirfenidona), čak ni pri koncentracijama ili dozama značajno većima od onih koje se povezuju s aktivnošću samog pirfenidona.
In vitro and in vivo tests did not indicate a genotoxic potential of tacrolimus.
In vitro i in vivo testovi nisu pokazali da je takrolimus genotoksičan.
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 M) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 M) at concentrations that are significantly greater than peak plasma concentrations observed in patients.
Ispitivanja apiksabana in vitro pokazala su da on nema inhibicijski učinak na aktivnost CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 i CYP3A4 (IC50 > 45 µm) te da je slab inhibitor aktivnosti CYP2C19 (IC50 > 20 µm) pri koncentracijama koje su značajno više od vršne koncentracije lijeka u plazmi zabilježene u bolesnika.
In vitro assays showed that brivaracetam disposition should not be significantly affected by CYP (eg.
Testovi in vitro pokazali su da na dispoziciju brivaracetama ne bi trebali značajno utjecati inhibitori CYP enzima (npr.
In vitro assessment of drug interactions
In vitro procjena interakcije s drugim lijekovima
In vitro binding assays confirmed that ixekizumab does not bind to human Fc receptors I, IIa, and IIIa or to complement component C1q.
Testovi vezivanja in vitro potvrdili su da se iksekizumab ne vezuje za humane receptore Fc I, IIa i IIIa niti za komponentu komplementa C1q.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02 – 200 μg/ml.
Vezivanje emtricitabina za proteine u ljudskoj plazmi in vitro iznosilo je < 4% i nije ovisilo o koncentraciji u rasponu od 0,02 do 200 µg/ml.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/ml.
In vitro vezanje emtricitabina na humane proteine plazme bilo je < 4% i nije ovisilo o koncentraciji u rasponu od 0,02 do 200 µg/ml.
In vitro binding of lenvatinib to human plasma proteins is high and ranged from 98% to 99% (0.3 - 30 μg/mL, mesilate).
In vitro, lenvatinib se u visokom postotku veže za proteine ljudske plazme i to u rasponu od 98% do 99% (0,3 - 30 μg/ml, mesilat).
In vitro binding of tildipirosin to bovine plasma and bronchial fluid proteins is limited with approximately 30%.
In vitro vezanje tildipirosina na proteine u plazmi goveda ograničeno je na 30%.
In vitro binding studies have not shown interference of flutemetamol (18F) binding to β-amyloid plaques in the presence of other common medicinal products taken by AD patients.
Ispitivanja vezivanja in vitro nisu pokazala interferenciju flutemetamola (18F) prilikom vezanja sa β-amiloidnim plakovima uz prisutnost drugih uobičajenih lijekova koje uzimaju bolesnici s AB-om.
In vitro combination of simeprevir with interferon, ribavirin, NS5A or NS5B inhibitors resulted in additive or synergistic effects.
In vitro kombinacija simeprevira s interferonom, ribavirinom, NS5A ili NS5B inhibitorima rezultirala je aditivnim ili sinergističkim učincima.
In vitro data also show that olaparib is not a substrate for OATP1B1, OATP1B3, OCT1, BCRP or MRP2 and not an inhibitor of OATP1B3, OAT1 or MRP2.
In vitro podaci pokazuju i da olaparib nije supstrat za OATP1B1, OATP1B3, OCT1, BCRP ili MRP2 niti inhibitor OATP1B3, OAT1 ili MRP2.
In vitro data indicate that ambrisentan at 300 μM resulted in less than 50 % inhibition of UGT1A1, UGT1A6, UGT1A9, UGT2B7 (up to 30%) or of cytochrome P450 enzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 (up to 25%).
In vitro podaci pokazuju da je ambrisentan u koncentraciji od 300 µM uzrokovao manje nego 50%- tnu inhibiciju UGT1A1, UGT1A6, UGT1A9, UGT2B7 (do 30%) te enzima citokroma P450: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 i 3A4 (do 25%).
In vitro data indicate that enzalutamide is not a substrate for OATP1B1, OATP1B3, or OCT1; and N-desmethyl enzalutamide is not a substrate for P-gp or BCRP.
In vitro podaci pokazuju da enzalutamid nije supstrat za OATP1B1, OATP1B3 ili OCT1; i N-desmetil enzalutamid nije supstrat za P-gp ili BCRP.
In vitro data indicate that gefitinib is a substrate for the membrane transport protein Pgp.
Podaci dobiveni in vitro ukazuju da je gefitinib supstrat za membranski transportni protein Pgp.
In vitro data indicate that inhibition of P-pg and BCRP by abacavir cannot be excluded at intestinal level.
In vitro podaci pokazuju da se ne može isključiti mogućnost da će abakavir inhibirati P-gp i BCRP u crijevima.
In vitro data indicate that ketoconazole is an inhibitor of CYP1A2 and does not significantly inhibit CYP 2A6 and 2E1.
In vitro podaci pokazuju da je ketokonazol inhibitor CYP1A2 te da ne inhibira CYP2A6 i 2E1 u značajnoj mjeri.
In vitro data indicate that regorafenib is a competitive inhibitor of the cytochromes CYP2C8 (Ki value of 0.6 micromolar), CYP2C9 (Ki value of 4.7 micromolar), CYP2B6 (Ki value of 5.2 micromolar) at concentrations which are achieved in vivo at steady state (peak plasma concentration of
In vitro podaci pokazuju da je regorafenib kompetitivni inhibitor citokroma CYP2C8 (Ki vrijednost od 0,6 µmol), CYP2C9 (Ki vrijednost od 4,7 µmol), CYP2B6 (Ki vrijednost od 5,2 µmol) u koncentracijama koje se postižu in vivo u stanju dinamičke ravnoteže (vršna koncentracija u plazmi od 8,1 µmol).
In vitro data indicate that regorafenib is metabolized by cytochrome CYP3A4 and uridine diphosphate glucuronosyl transferase UGT1A9.
In vitro podaci pokazuju da regorafenib metaboliziraju citokrom CYP3A4 i uridin-difosfat- glukuronozil transferaza UGT1A9.
In vitro data indicate that selexipag could be an inducer of both CYP3A4 and CYP2C9 in the intestine.
In vitro podaci upućuju na mogućnost da je seleksipag induktor i CYP3A4 i CYP2C9 u crijevu.
In vitro data indicate that the following species are not susceptible to ceftolozane/tazobactam:
In vitro podaci ukazuju da sljedeće vrste nisu osjetljive na ceftolozan/tazobaktam:
In vitro data indicate that ulipristal acetate may be an inhibitor of BCRP (Breast Cancer Resistance Protein) transporters at the intestinal level.
In vitro podaci ukazuju da ulipristalacetat može biti inhibitor prijenosnika proteina otpornosti raka dojke na lijekove (BCRP) u crijevima.
In vitro data indicated a low potential for interaction with other antiepileptic medicinal products (see section 5.2).
Podaci in vitro ukazivali su na niski potencijal za interakciju s drugim antiepileptičkim lijekovima (vidjeti dio 5.2).
In vitro data indicated that drug-drug interactions with afatinib due to inhibition of UGT1A1 are considered unlikely.
In vitro podaci ukazuju da se interakcije lijekova s afatinibom zbog inhibicije UGT1A1 ne smatraju vjerojatnima.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O- desmethyl metabolite.
Podaci in vitro pokazuju da su CYP2C9, CYP2C19 i CYP3A4 sposobni katalizirati stvaranje O-dezmetil metabolita.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo.
Podaci in vitro pokazuju da su CYP2C9, CYP2C19 i CYP3A4 sposobni katalizirati stvaranje O- dezmetilnog metabolita, ali glavni izoenzim koji u tome sudjeluje nije potvrđen in vivo.
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo..
Podaci in vitro pokazuju da su CYP2C9, CYP2C19 i CYP3A4 sposobni katalizirati stvaranje O- dezmetilnog metabolita, ali glavni izoenzim koji u tome sudjeluje nije potvrđen in vivo.
In vitro data suggest that brivaracetam has a low interaction potential.
In vitro podaci ukazuju na to da brivaracetam ima nizak interakcijski potencijal.
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by uridine 5'-diphosphoglucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7.
Podaci in vitro sugeriraju da je primarni put metabolizma empagliflozina u ljudi glukuronidacija pomoću uridin 5’-difosfoglukuronoziltransferaza UGT1A3, UGT1A8, UGT1A9 i UGT2B7.